Researchers and global experts have renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS).

The change aims to shift the medical understanding of the condition from a localized ovarian issue to a complex, multisystem disease. By updating the terminology, health professionals hope to improve diagnosis rates and ensure patients receive more comprehensive care.

The previous name, Polycystic Ovary Syndrome, focused heavily on the presence of cysts on the ovaries. However, the new designation, Polyendocrine Metabolic Ovarian Syndrome, highlights the endocrine and metabolic disruptions that characterize the disorder. This shift follows more than a decade of research and advocacy [1].

Experts said the rename is intended to reduce the stigma caused by decades of misunderstanding. Because the condition affects multiple systems in the body, a more accurate name helps clinicians look beyond the ovaries to treat the whole patient. This holistic approach is critical given the widespread nature of the syndrome.

Data indicates that the condition affects one in eight women worldwide [2]. The prevalence underscores the necessity for a standardized, accurate naming convention to streamline awareness and medical intervention across different healthcare systems globally.

Medical providers are encouraged to adopt the PMOS terminology to better communicate the systemic nature of the disease to patients. The transition is expected to facilitate better integration of metabolic health and endocrine management in primary care settings.

“The change aims to shift the medical understanding of the condition from a localized ovarian issue to a complex, multisystem disease.”

The transition from PCOS to PMOS represents a fundamental shift in clinical framing. By moving away from a name that implies the disease is limited to the ovaries, the medical community is acknowledging the metabolic and hormonal drivers of the syndrome. This change is likely to lead to more integrated treatment plans that prioritize insulin resistance and endocrine health alongside reproductive care.